Eczema and Blood Clots: Small Absolute Differences and Conflicting Cohorts Need the Same Page
Dr. Arsy Editorial education, checked November 9, 2026. Sources do not endorse #003. This does not replace individualized medical care.
A blood-clot headline can sound like a reason to stop a prescribed eczema medicine or start aspirin. These cohort studies support neither decision on their own. Research on venous thromboembolism, or VTE, needs both absolute event rates and the differences between study populations. VTE includes deep-vein thrombosis and pulmonary embolism; it is not interchangeable with an arterial heart attack or stroke.
Taiwan: a higher relative estimate beside a small rate difference
A 2023 nationwide cohort matched 142,429 adults aged 20 or older with newly diagnosed eczema to 142,429 without it. Mean follow-up was approximately 7.15 and 7.09 years, respectively. The eczema definition used repeated outpatient or discharge diagnoses, rather than a new examination of every participant.
| Finding | Numbers | Interpretation |
|---|---|---|
| Taiwan eczema cohort | 1,066 VTE events; 1.05 per 1,000 person-years | Approximately 0.7% experienced VTE over follow-up. |
| Taiwan comparator cohort | 829 events; 0.82 per 1,000 person-years | Approximately 0.6% over follow-up. |
| Taiwan overall association | HR 1.28; 95% CI 1.17–1.40 | A 28% relative hazard difference, not a 28% absolute probability. |
| Swedish overall adjusted association | aHR 1.04; 95% CI 1.01–1.09 | A small estimate close to one; its interval nevertheless excluded one. |
Subtracting the Taiwanese reported incidence rates gives 0.23 events per 1,000 person-years, or about 23 per 100,000 person-years. This calculated crude rate difference is not an adjusted lifetime-risk estimate. Claims data lacked direct information on smoking, BMI, activity and several other potential influences. Treatment-based severity classification and coding misclassification were additional limitations.
A newer Swedish cohort did not reproduce one simple overall story
The Swedish primary report, published online in 2025, included 210,492 adults with eczema and 1,048,395 controls, with follow-up ending December 2023. Its crude rates were 1.49 versus 1.71 per 1,000 person-years, respectively. Yet the adjusted overall HR was 1.04. Crude population rates and an adjusted hazard ratio answer different questions; it would be wrong to call the adjusted estimate protective simply because the crude rate was lower.
The authors characterized overall risk as similar. The printed confidence interval, 1.01–1.09, should still be retained rather than described as statistically nonsignificant. Severe eczema—defined through systemic treatment or hospitalization—had a higher estimate, aHR 1.93 (95% CI 1.70–2.14). The severe-disease subgroup aged 18–39 had aHR 2.95 (95% CI 2.40–3.59), not an estimate for every young person with any eczema.
The populations, age ranges, definitions and measured adjustments differed. Neither observational study proves eczema itself caused a clot, or provides a drug-specific causal estimate. The Swedish discussion here is based on its actual primary abstract; no inaccessible full-paper analysis is claimed.
Symptoms matter more than reassurance from a small average
The CDC clot guide lists unexplained limb swelling, tenderness, warmth or discoloration as reasons for prompt medical assessment. Difficulty breathing, chest pain or coughing blood can indicate pulmonary embolism and require immediate medical help. A low average absolute risk does not make these symptoms safe to ignore.
Do not start aspirin or an anticoagulant, or stop an eczema prescription, based on this article. Ask the prescriber how personal history, other medicines, immobility and treatment options affect your own risk. An individual prevention plan requires assessment; no eczema-only anticoagulation policy was tested here.
For distinct background questions, read about sleep and activity, infection outcomes during dupilumab trials, cohort-versus-causality research and heterogeneous migraine evidence. These do not provide a diagnosis for new chest or limb symptoms.
Dr. Arsy Moisturizer #003 supports cosmetic hydration and moisture-barrier support. It does not prevent blood clots, treat vascular symptoms or treat eczema.